| Issue |
Med Sci (Paris)
Volume 21, Décembre 2005
Métabolisme glucidolipidique et risque cardiovasculaire: Nouvelle approches
|
|
|---|---|---|
| Page(s) | 66 - 68 | |
| Section | M/S revues | |
| DOI | https://doi.org/10.1051/medsci/20052111s66 | |
| Published online | 15 November 2005 | |
Les médicaments orphelins en Europe
Orphan medicinal products in Europe
Représentant français au comité des médicaments orphelins (EMEA), Service de Médecine Interne, CHNO des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France
Cet article explicite les mesures incitatives de la législation européenne de 1999 pour le développement des médicaments orphelins, et en dresse un bilan à 5 ans
Abstract
Incentives provided by the 1999 European regulation for the development of orphan drugs are described, and a picture of their outcome 5 years after is shown.
© 2005 médecine/sciences - Inserm / SRMS
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.